Immune-Onc Therapeutics

Immune-Onc Therapeutics, Inc. (“Immune-Onc”) is a clinical-stage cancer immunotherapy company dedicated to the discovery and development of novel myeloid checkpoint inhibitors for cancer patients. Headquartered in Palo Alto, California, Immune-Onc has assembled a diverse team with deep expertise in drug development and proven track records of success at leading biotechnology companies.

The company aims to translate unique scientific insights in myeloid cell biology and immune inhibitory receptors to discover and develop first-in-class biotherapeutics that disarm immune suppression in the tumor microenvironment. Immune-Onc has a promising pipeline with a current focus on targeting the Leukocyte Immunoglobulin-Like Receptor subfamily B (LILRB) of myeloid checkpoints. The company has strategic research collaborations with The University of Texas, Albert Einstein College of Medicine, and Memorial Sloan Kettering Cancer Center, and has invested in proprietary models, assays and tools to interrogate the biology and translate this cutting-edge research into the development of novel therapies.

Immune-Onc’s lead program IO-202, a first-in-class antibody targeting LILRB4 (also known as ILT3), is being developed to treat acute myeloid leukemia (AML) and other cancers. IO-202 is the first T-cell activator for AML. In September 2020, Immune-Onc initiated a Phase I trial evaluating IO-202 in blood cancers, AML and chronic myelomonocytic leukemia (CMML). The company plans to evaluate IO-202 in solid tumors and in other forms of blood cancer in the near future. In addition to IO-202, Immune-Onc’s pipeline includes IO-108, an antibody targeting LILRB2 (also known as ILT4) in the IND-enabling stage of development. Additional preclinical candidates focused on myeloid checkpoints include an anti-LAIR1 antibody and multiple undisclosed programs for solid tumors and hematologic malignancies. For more information, please visit www.immune-onc.com.